Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunisation with FIV vaccines

被引:15
作者
Tellier, MC [1 ]
Soos, J [1 ]
Pu, RY [1 ]
Pollock, D [1 ]
Yamamoto, JK [1 ]
机构
[1] UNIV FLORIDA,SCH VET MED,DEPT PATHOBIOL,GAINESVILLE,FL 32611
关键词
FIV; cytolytic T-lymphocytes; conventional vaccines;
D O I
10.1016/S0378-1135(97)00081-3
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Vaccine protection has been achieved in cats against experimental infection with feline immunodeficiency virus (FIV). Such protection has been attributed to FIV-specific humoral immunity, as well as cellular immunity of unknown mechanism(s). Since cell-mediated immunity plays a crucial role in the clearance of viral infections, this study evaluated the role of FIV-specific CTL in vaccine prophylaxis. Cats were immunised with inactivated FIV vaccines, reported to have > 90% vaccine efficacy, Significant levels of specific CTL activity were detected following the third immunisation. CTL activity persisted for several months and could be enhanced through a booster immunisation. The levels of CTL activity were comparable to those induced by a recombinant canarypoxvirus based FIV vaccine. These results suggest a possible role for CTL-mediated immunity in vaccine protection against FIV infection in cats. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 35 条
[1]   IMMUNOLOGICAL ABNORMALITIES IN PATHOGEN-FREE CATS EXPERIMENTALLY INFECTED WITH FELINE IMMUNODEFICIENCY VIRUS [J].
ACKLEY, CD ;
YAMAMOTO, JK ;
LEVY, N ;
PEDERSEN, NC ;
COOPER, MD .
JOURNAL OF VIROLOGY, 1990, 64 (11) :5652-5655
[2]   IMMUNOLOGICAL ADJUVANTS - DESIRABLE PROPERTIES AND SIDE-EFFECTS [J].
ALLISON, AC ;
BYARS, NE .
MOLECULAR IMMUNOLOGY, 1991, 28 (03) :279-284
[3]   FORMALIN INACTIVATION OF VESICULAR STOMATITIS-VIRUS IMPAIRS T-CELL- BUT NOT T-HELP-INDEPENDENT B-CELL RESPONSES [J].
BACHMANN, MF ;
KUNDIG, TM ;
KALBERER, CP ;
HENGARTNER, H ;
ZINKERNAGEL, RM .
JOURNAL OF VIROLOGY, 1993, 67 (07) :3917-3922
[4]   IMMUNOGENICITY OF A VIRAL MODEL VACCINE AFTER DIFFERENT INACTIVATION PROCEDURES [J].
BACHMANN, MF ;
BAST, C ;
HENGARTNER, H ;
ZINKERNAGEL, RM .
MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 1994, 183 (02) :95-104
[5]  
BACHMANN MF, 1994, EUR J IMMUNOL, V24, P2128
[6]   EFFECT OF A MEMBRANE-ACTIVE AGENT ON UPTAKE OF ADRIAMYCIN IN LEWIS LUNG-CARCINOMA CELLS DERIVED FROM PRIMARY AND METASTATIC GROWTHS [J].
BARSHIRAMAYMON, B ;
MICHOWITZ, M ;
GIBLI, O ;
KLEIN, O ;
PINCHASOV, A ;
LEIBOVICI, J .
CHEMOTHERAPY, 1992, 38 (01) :66-73
[7]   POTENTIAL USE OF NONREPLICATING VECTORS AS RECOMBINANT VACCINES [J].
BAXBY, D ;
PAOLETTI, E .
VACCINE, 1992, 10 (01) :8-9
[8]   HIV-1 PROTEINS IN INFECTED-CELLS DETERMINE THE PRESENTATION OF VIRAL PEPTIDES BY HLA CLASS-I AND CLASS-II MOLECULES AND THE NATURE OF THE CELLULAR AND HUMORAL ANTIVIRAL IMMUNE-RESPONSES - A REVIEW [J].
BECKER, Y .
VIRUS GENES, 1994, 8 (03) :249-270
[9]   ADJUVANT FORMULATION FOR USE IN VACCINES TO ELICIT BOTH CELL-MEDIATED AND HUMORAL IMMUNITY [J].
BYARS, NE ;
ALLISON, AC .
VACCINE, 1987, 5 (03) :223-228
[10]   INDUCTION OF CYTOTOXIC T-LYMPHOCYTES BY RECOMBINANT CANARYPOX (ALVAC) AND ATTENUATED VACCINIA (NYVAC) VIRUSES EXPRESSING THE HIV-1 ENVELOPE GLYCOPROTEIN [J].
COX, WI ;
TARTAGLIA, J ;
PAOLETTI, E .
VIROLOGY, 1993, 195 (02) :845-850